Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for biotechnology industry professionals · Friday, March 29, 2024 · 699,665,835 Articles · 3+ Million Readers

Carglumic Acid Market Value to Reach US$ 187.0 Million by the End of 2026: Transparency Market Research

Carglumic Acid Market (Delivery Format- Tablet, orally disintegrating, Tablet, for suspension; Distribution Channel- Hospital Pharmacies, Retail Pharmacies, E-Commerce) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2026

Albany – NY, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Carglumic acid is an orphan drug that is used for treating patients suffering from hyperammonemia, a urea cycle disorder that is caused due to the lack of a certain enzyme in the liver. This also implies deficiency of N-acetylglutamate (NAG) synthase. Carglumic acid helps in detoxification and removal of ammonia from blood cells.

According to a study by Transparency Market Research (TMR), the global market for carglumic acid is likely to witness strong growth. The market is projected to register 7.5% CAGR during the forecast period 2017-2026. It is also estimated to bring in US$ 187.0 million revenue by the end of 2026.

View Research Report Overview at https://www.transparencymarketresearch.com/carglumic-acid-market.html

Carglumic acid is on the verge of becoming an indispensable tool for managing life-threating metabolic disorders that affect the urea cycle. Carglumic acid is also being used in enhancing ammonia detoxification in patients with organic acidurias. Recently, carglumic acid has also shown potential for anti-tumor activity in breast cancer. Carglumic acid activates caspase 3 which helps in promoting cell apoptosis and also suppress tumor growth. Meanwhile, new formulations are also being developed by leading pharmaceutical companies to effectively treat urea cycle disorders and also to strengthen their product portfolio. In order to prevent brain damage in children, researchers have also combined metabolomics analysis of carglumic acid with genome sequencing.

Request to View Sample Copy of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=35954

The report also offers a detailed profile of some of the leading players in the global market for carglumic acid such as Dipharma Francis S.r.l, Recordati S.p.A, and Civentichem, LLC.

The global market for carglumic acid is segmented on the basis of distribution channel, delivery format, and region. On the basis of delivery format, the market segment includes Tablet, for suspension and Tablet, orally disintegrating. Among these, tablet, for suspension is likely to account for maximum revenue share in the global market for carglumic acid between 2017 and 2026.

On the basis of distribution channel, the market is segmented into Hospital Pharmacies. E-Commerce, and Retail Pharmacies. High sales is expected through hospital pharmacies during the forecast period 2017-2026.

Request Carglumic Acid Market Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35954

North America to Account for the Highest Growth in the Global Carglumic Acid Market

Geographically, the market is segmented into Asia Pacific Excluding Japan (APEJ), Japan, Europe, North America, Latin America, and the Middle East and Africa (MEA). North America is likely to be one of the largest regions in the global market for carglumic acid market. Owing to the Increasing incidence of hyperammonemia in North America, carglumic acid is gaining popularity among the healthcare professionals in the region. Moreover, pharmaceutical companies and the regulatory bodies in the region are also focusing on creating an awareness about carglumic acid, along with its dosage and use. Meanwhile, Europe is also likely to witness significant growth in the global carglumic acid market in the near future. High prevalence of NAGS deficiency among the European population, especially among the newborns. Hence, the demand for effective treatment that can help in pulling high ammonium levels to normal is also increasing. Moreover, Orphan Europe, a leading company in orphan drugs in Europe has developed Carbaglu (carglumic acid). Carbaglu is also the first drug that has been approved by the Food and Drug Administration (FDA) for treating NAGS deficiency. 

Global Carglumic Acid Market Report is available @ US$ 5795

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact

Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
TMR Blog: http://www.theglobalhealthnews.com/

Primary Logo

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release